Use of antivitamin K in current medical practice;Utilisation des antivitamines K en pratique medicale courante

Sang Thrombose Vaisseaux

Volumn 12, Issue SPEC. ISS., 2000, Pages 26-39

  Schved, J F ^a   De Moerloose, P ^a   Jude, B ^a   Toulon, P ^a  

^a HÔPITAL SAINT ELOI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; AMIODARONE; ANABOLIC AGENT; ANTIVITAMIN K; BARBITURIC ACID DERIVATIVE; CARBAMAZEPINE; CEPHALOSPORIN DERIVATIVE; CIMETIDINE; CLOPIDOGREL; COLESTYRAMINE; COUMADINE; ERYTHROMYCIN; ESTROGEN; FIBRIC ACID DERIVATIVE; FLUINDIONE; GRISEOFULVIN; ISONIAZID; METRONIDAZOLE; NAFCILLIN; NONSTEROID ANTIINFLAMMATORY AGENT; PHENINDIONE; PHENPROCOUMON; PHENYTOIN; PROTHROMBIN COMPLEX; RIFAMPICIN; THYROID HORMONE DERIVATIVE; TIOCLOMAROL; UNINDEXED DRUG; VITAMIN K GROUP; WARFARIN;

ANTICOAGULANT THERAPY; BLEEDING; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG HALF LIFE; DRUG INDICATION; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENTIATION; ESTROGEN THERAPY; HUMAN; INTERNATIONAL STANDARD UNIT; ORAL CONTRACEPTION; POSTOPERATIVE COMPLICATION; REVIEW; RISK; THROMBOEMBOLISM; VEIN THROMBOSIS;

EID: 0033652988     PISSN: 09997385     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Warfarin or acenocoumarol; which is better in the management of oral anticoagulants?
2. Oral anticoagulants. Mechanism of action, clinical effectiveness and optimal therapeutic range
3. Laboratory monitoring of oral anticoagulant therapy
4. Les variables preanalytiques en hemostase. Recommandations du Groupe d'Etudes sur l'Hemostase et la Thrombose (GEHT)
5. A structured teaching and self-management program for patients receiving oral anticoagulation. A randomized controlled trial
6. Evaluation of a portable prothrombin time monitor for home use by patients who require long-term oral anticoagulant therapy
7. Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy
8. Antithrombotic therapy in children
9. Age-dependent differences in the anticoagulant effect of phencoupramon in patients after heart valve surgery
10. Safety of treatment with oral anticoagulants in the elderly. A systematic review
11. The use of antithrombotic agents during pregnancy
12. Anticoagulation and pregnancy
13. Is warfarin sodium contraindicated in the lactating mother?
14. Interference with oral anticoagulant treatment by estrogen. Influence of estrogen administration route
15. Low-dose oral vitamin K reliably reverses over-anticoagulation due to warfarin
16. Low-dose vitamin K1 versus short-term withholding of acenocoumarol in the treatment of excessive anticoagulation episodes induced by acenocoumarol
17. Guide sur le traitement anticoagulant par voie orale (traduction francaise)
18. Recommandations. Le traitement des hemorragies. Les hemorragies associees aux traitements antithrombotiques
19. Emergency oral anticoagulant reversal: The relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy
20. Guidelines on oral anticoagulation. Third Edition
21. Management of anticoagulation before and after elective surgery
22. Antithrombotic therapy in atrial fibrillation
23. Warfarin pretreatment does not lead to increased bleeding tendency during cardiac surgery
24. Comparing different routes and doses of phytonadione for reversing excessive anticoagulation
25. Vitamin K metabolism in a patient resistant to vitamin K antagonists
26. Determinants of compliance with anticoagulation: A case-control study
27. Anticoagulant therapy with coumarin agents in hemostasis and thrombosis: Basic principles and clinical practice, 3rd edition
28. Optimal duration of oral anticoagulant therapy: A randomised trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis
29. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism
30. A comparison of three months of anticoagulation with extended coagulation for a first episode of idiopathic venous thromboembolism
31. Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism
32. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism
33. The risk of recurrent venous thromboembolism in patients with an Arg506 → Gln mutation in the gene for factor V (Factor V Leiden)
34. Bleeding complications of oral anticoagulant treatment: An inception-cohort, prospective, collaborative study: (ISCOAT)
35. Comparison of an anticoagulation clinic and usual medical care: Anticoagulation control, patient outcomes and health care costs